Related Experiment Video
Updated: Jun 23, 2025
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
9.5K
MET Oncogene Targeting for Cancer Immunotherapy
Andrea Maria Lombardi1, Dario Sangiolo1, Elisa Vigna1
1Department of Oncology, University of Torino, 10043 Torino, Italy.
International Journal of Molecular Sciences
|June 19, 2024
Summary
Targeting the MET receptor tyrosine kinase, a key driver of invasive growth and cancer, offers new therapeutic strategies. This review explores MET inhibition
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- The MET receptor tyrosine kinase drives invasive growth, crucial for development but hijacked by cancer.
- MET is a significant oncogene; its inhibition is a long-standing cancer therapy goal.
- MET (over)expression is a hallmark of cancer cell transformation.
Purpose of the Study:
- To evaluate targeting MET within cancer immunotherapy strategies.
- To explore MET's role as a malignancy driver and treatment potentiator.
- To review therapeutic opportunities involving MET inhibition and immune functions.
Main Methods:
- Literature review of MET signaling pathways.
- Analysis of MET's role in cancer development and progression.
- Evaluation of MET inhibition in combination with immunotherapy.
Main Results:
- MET signaling is implicated in tumor invasiveness and metastasis.
- MET inhibition can be crucial for effective anti-cancer immune responses.
- Blocking MET can enhance the efficacy of other cancer treatments.
Conclusions:
- Targeting MET presents a dual opportunity in cancer therapy: direct anti-tumor effect and immune potentiation.
- Integrating MET inhibition with immunotherapy warrants further investigation.
- MET-targeted therapies, especially in combination, hold promise for improving cancer treatment outcomes.
Keywords:
MET antibodyMET oncogeneMET tyrosine kinase inhibitorscellular immunotherapyimmunotherapytargeted therapyMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K